The firms will have exclusive access for a limited time to the data from the first 50,000 individuals with samples in the biobank to be sequenced.
The study seeks to identify biomarkers that can help personalize treatment for patients by identifying signs of rapid decline in kidney function.
GlaxoSmithKline and Verily Life Sciences form Galvani Bioelectronics.
Drug developers and genetic testing firms are contemplating how best to share variant classification data while protecting their commercial interests.
Five people have been indicted for stealing trade secrets from GlaxoSmithKline, the Wall Street Journal reports.
Therapies aimed at drug targets that have been linked genetically to disease fare better through the drug development pipeline, researchers from GSK and elsewhere found.
The institute will develop new technologies and approaches to decode how genes are controlled and how a cell's "operating system" functions.
Originally published Oct. 3.
NEW YORK (GenomeWeb) – A team led by researchers at Cellzome, a part of GlaxoSmithKline's R&D division, has developed a thermal profiling-based method for identifying protein drug targets and measuring protein-drug binding.
Originally published Sept. 30.
Dog DNA testing finds that some purebreds might not truly be purebreds, Inside Edition reports.
Mary Beckerle has returned as director of the Huntsman Cancer Institute, according to ScienceInsider.
Smithsonian Magazine reports that environmental DNA sampling can be used to track elusive organisms.
In Genome Research this week: repetitive satellite DNA in the fruit fly, transcriptome map assembly pipeline, and more.